The Characteristics and Mortality of Osteoporosis, Osteomyelitis, or Rheumatoid Arthritis in the Diabetes Population: A Retrospective Study

Abstract

Background. Patients with diabetes mellitus are prone to develop osteoporosis, osteomyelitis, or rheumatoid arthritis (RA). Furthermore, the presence of these complications in those with diabetes may lead to higher mortality. The aim of our study was to assess characteristics and mortality of osteoporosis, osteomyelitis, or rheumatoid arthritis in individuals with diabetes. Methods. We analyzed osteoporosis, osteomyelitis, and RA deaths associated with diabetes from 1999–2017 using the CDC WONDER system (CDC WONDER; https://wonder.cdc.gov). We used ICD-10 codes to categorize the underlying and contributing causes of death. Crude mortality rates (CMR) and age-adjusted mortality rates (AAMR) per 1,000,000 person-years were calculated. Results. The AAMR for osteoporosis in the population with diabetes was significantly higher in females (AAMR: 4.17, 95% CI: 4.10–4.24) than in males (AAMR: 1.12, 95% CI: 1.07–1.16). Deaths due to osteoporosis increased gradually from 1999, peaked in 2003 (AAMR: 3.78, 95% CI: 3.55–4.00), and reached a nadir in 2016 (AAMR: 2.32, 95% CI: 2.15–2.48). The AAMR for RA associated with diabetes was slightly higher in females (AAMR: 4.04, 95% CI: 3.98–4.11) than in males (AAMR: 2.45, 95% CI: 2.39–2.51). The mortality rate due to RA increased slightly from 1999 (AAMR: 3.18, 95% CI: 2.97–3.39) to 2017 (AAMR: 3.20, 95% CI: 3.02–3.38). The AAMR for osteomyelitis associated with diabetes was higher in males (AAMR: 4.36, 95% CI: 4.28–4.44) than in females (AAMR: 2.31, 95% CI: 2.26–2.36). From 1999 to 2017, the AAMR from osteomyelitis in this population was 2.63 (95% CI: 2.44–2.82) per 1,000,000 person-years in 1999 and 4.25 (95% CI: 4.05–4.46) per 1,000,000 person-years in 2017. Conclusions. We found an increase in the age-adjusted mortality rates of RA and osteomyelitis and a decrease of osteoporosis associated with diabetes from 1999 to 2017. We suggest that increased attention should therefore be given to these diseases in the population with diabetes, especially in efforts to develop preventative and treatment strategies.

Nanohydroxyapatite (nHAp) Doped with Iron Oxide Nanoparticles (IO), miR-21 and miR-124 Under Magnetic Field Conditions Modulates Osteoblast Viability, Reduces Inflammation and Inhibits the Growth of Osteoclast – A Novel Concept for Osteoporosis Treatment: Part 1

“… 3 Moreover, treatment with glucocorticoids, diabetes mellitus type 1 and 2 (T1D and T2D, respectively), rheumatoid arthritis, multiple myeloma or liver associated disorders has been shown as a secondary cause of osteoporosis. 4 As estimated by the National Health Institute (NIH), more than 200 million patients worldwide are affected by osteoporosis. Additionally, the International Osteoporosis Foundation has calculated that 1 in 3 women over the age of 50 and 1 in 5 men will suffer from osteoporosis-related bone fractures in their lives.…”

Influence of type 2 diabetes microangiopathy on bone mineral density and bone metabolism: A meta-analysis

“…With the aging of the population, the incidence of osteoporosis is increasing. Factors, such as diabetes, aging and lack of physical activity, may cause bone loss [ 31 , 32 ]. Diabetes and its complications, especially diabetic microangiopathy, not only coexist with osteopenia and osteoporosis but also influence the development of other diseases.…”

Antimicrobial Susceptibility of <em>Staphylococcus aureus</em> to Anti-inflammatory Drugs With a Focus on the Combinatory Effect of Celecoxib With Oxacillin In Vitro

“…Similarly, septic arthritis is an infection of the joints induced by the colonisation of the joint cavity by bacteria leading to irreversible destruction of the joints despite antibiotics intervention [11,12]. Both these conditions are associated with patient morbidity and mortality [13,14]. Epidemiological data from Germany showed an osteomyelitis incidence rate of 17 cases per 100,000 inhabitants [15].…”